New obesity drug aims to cut side effects with smarter dosing
NCT ID NCT06718998
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 24 times
Summary
This early-stage study tested a new medicine called NNC0519-0130 in 134 overweight or obese adults. The goal was to see if different ways of slowly increasing the dose could reduce side effects. Participants were assigned by chance to one of four dosing schedules and were followed for about 24 weeks. The study focused on safety and how well people tolerated the medicine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of Graz
Graz, 8010, Austria
Conditions
Explore the condition pages connected to this study.